Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$8.22 +0.2%	$8.41	$3.51 ▼ $14.44	$701.76M	0.68	1.21 million shs	308,135 shs
DMAC DiaMedica Therapeutics	$3.90 -3.2%	$3.94	$2.14 ▼ $6.82	$167.24M	1.23	85,277 shs	85,686 shs
IMNM Immunome	$9.79 +3.2%	$8.06	$5.15 ▼ $16.81	$851.85M	1.94	918,342 shs	814,483 shs
NRIX Nurix Therapeutics	$11.96 -5.3%	$10.52	$8.18 ▼ $29.56	$911.78M	2.15	884,841 shs	891,867 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+0.99%	+6.22%	-4.09%	-8.89%	+121.62%
DMAC DiaMedica Therapeutics	-2.18%	-4.05%	+5.22%	-28.92%	+54.41%
IMNM Immunome	-0.84%	+5.21%	+19.52%	+6.27%	-39.55%
NRIX Nurix Therapeutics	-1.25%	+3.87%	+24.07%	-4.25%	-21.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.9276 of 5 stars	3.7	0.0	4.7	3.6	0.8	0.6
DMAC DiaMedica Therapeutics	1.35 of 5 stars	3.5	1.0	0.0	2.5	0.0	0.0
IMNM Immunome	1.7865 of 5 stars	3.5	0.0	0.0	2.8	2.5	0.0
NRIX Nurix Therapeutics	2.1429 of 5 stars	4.4	1.0	0.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	435.28% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	105.13% Upside
IMNM Immunome	3.00	Buy	$23.33	138.34% Upside
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	152.31% Upside

Current Analyst Ratings Breakdown

Latest DMAC, NRIX, AVXL, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/9/2025	NRIX Nurix Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $25.00
4/9/2025	NRIX Nurix Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $35.00
4/9/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/2/2025	IMNM Immunome	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
4/2/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/31/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
IMNM Immunome	$10.94M	77.88	N/A	N/A	$2.77 per share	3.53
NRIX Nurix Therapeutics	$56.42M	16.16	N/A	N/A	$7.44 per share	1.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	8/5/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.64	N/A	N/A	N/A	N/A	-43.67%	-40.81%	8/6/2025 (Estimated)
IMNM Immunome	-$106.81M	-$3.18	N/A	N/A	N/A	-3,014.59%	-48.63%	-41.62%	8/11/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-354.85%	-53.65%	-38.59%	7/10/2025 (Estimated)

Latest DMAC, NRIX, AVXL, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million
3/19/2025	Q4 2024	IMNM Immunome	-$0.68	-$0.84	-$0.16	-$1.28	$3.07 million	$2.74 million
3/17/2025	Q4 2024	DMAC DiaMedica Therapeutics	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
DMAC DiaMedica Therapeutics	N/A	11.81	11.81
IMNM Immunome	N/A	6.17	6.17
NRIX Nurix Therapeutics	N/A	6.46	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
DMAC DiaMedica Therapeutics	10.12%
IMNM Immunome	44.58%
NRIX Nurix Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
DMAC DiaMedica Therapeutics	7.30%
IMNM Immunome	8.60%
NRIX Nurix Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.71 million	Optionable
DMAC DiaMedica Therapeutics	20	42.88 million	39.68 million	Optionable
IMNM Immunome	40	87.01 million	72.92 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.42 million	Optionable

DMAC, NRIX, AVXL, and IMNM Headlines

Recent News About These Companies

Nurix Therapeutics (NASDAQ:NRIX) Shares Down 5.9% - What's Next?

June 12 at 1:20 PM | marketbeat.com

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

June 12 at 7:00 AM | globenewswire.com

Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

June 11 at 10:57 PM | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Dexcom (DXCM) and Immunovant (IMVT)

June 10 at 4:02 PM | theglobeandmail.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages

June 10 at 1:42 AM | marketbeat.com

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European ...

June 7, 2025 | manilatimes.net

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

June 6, 2025 | globenewswire.com

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up - Time to Buy?

June 3, 2025 | marketbeat.com

Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?

June 3, 2025 | zacks.com

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

June 3, 2025 | finance.yahoo.com

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

June 2, 2025 | globenewswire.com

Two Sigma Investments LP Purchases 84,375 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

June 1, 2025 | marketbeat.com

Nuveen Asset Management LLC Trims Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

May 31, 2025 | marketbeat.com

Nurix Therapeutics (NASDAQ:NRIX) Trading 3.9% Higher - Should You Buy?

May 30, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Position Boosted by Wellington Management Group LLP

May 30, 2025 | marketbeat.com

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Millennium Management LLC Grows Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

May 27, 2025 | marketbeat.com

Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

May 25, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Acquires 40,001 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

May 23, 2025 | marketbeat.com

Nurix Therapeutics reports stockholder voting results

May 21, 2025 | uk.investing.com

Velan Capital Investment Management LP Invests $1.84 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC, NRIX, AVXL, and IMNM Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$8.22 +0.02 (+0.24%)

As of 04:00 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

DiaMedica Therapeutics NASDAQ:DMAC

$3.90 -0.13 (-3.23%)

As of 04:00 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Immunome NASDAQ:IMNM

$9.79 +0.30 (+3.16%)

As of 04:00 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Nurix Therapeutics NASDAQ:NRIX

$11.96 -0.67 (-5.30%)

As of 04:00 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time